Results 271 to 280 of about 113,596 (299)
Some of the next articles are maybe not open access.
Induction of TAp63 by histone deacetylase inhibitors
Biochemical and Biophysical Research Communications, 2010TAp63 belongs to the p53-tumour suppressor family and is capable of transactivating a set of target genes to induce cell cycle arrest and apoptosis. We showed that treatment of cancer cells with chemo-therapeutic drugs or the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) results in induction of TAp63 expression, which is in turn related ...
Sayan, BS +7 more
openaire +4 more sources
Histone Deacetylase Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry, 2019Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways.
Yijie, Sun +4 more
openaire +2 more sources
Histone deacetylase inhibitors: gathering pace
Current Opinion in Pharmacology, 2006Reversible histone acetylation is one of the key mechanisms involved in the epigenetic control of gene expression. A variety of recent studies has revealed a role for acetylation in a much broader repertoire of physiological processes, including proliferation control and protein folding, and has highlighted how a variety of non-histone regulatory ...
Nessa, Carey, Nicholas B, La Thangue
openaire +2 more sources
Trifluoromethyl ketones as inhibitors of histone deacetylase
Bioorganic & Medicinal Chemistry Letters, 2002Trifluoromethyl ketones were found to be inhibitors of histone deacetylases (HDACs). Optimization of this series led to the identification of submicromolar inhibitors such as 20 that demonstrated antiproliferative effects against the HT1080 and MDA 435 cell lines.
Robin R, Frey +11 more
openaire +2 more sources
Histone deacetylase inhibitors in myelodysplastic syndrome
Best Practice & Research Clinical Haematology, 2004Histone deacetylase (HDAC) inhibitors are amongst the newer therapies being introduced in refractory, relapsed, and resistant disease. These agents are mechanism-based and their use is targeted to the diseased cell or tissue. HDACs are key enzymes in the regulation of gene expression.
Kapil, Bhalla, Alan, List
openaire +2 more sources
Histone deacetylase inhibitors: discovery and development as anticancer agents
Expert Opinion on Investigational Drugs, 2005Paul A MarkS, Miloš Dokmanović
exaly
Histone deacetylase inhibitors: from target to clinical trials
Expert Opinion on Investigational Drugs, 2002Paul A MarkS
exaly
Histone deacetylase inhibitors in cancer therapy
Expert Opinion on Investigational Drugs, 2007Ricky W Johnstone, H Miles Prince
exaly
Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry, 2020Loredana Cappellacci +2 more
exaly